Is a blood test alone sufficient to assess liver status?

No - blood tests and imaging (ultrasound) complement each other and together give a fuller clinical picture. Ultrasound assesses liver size and echogenicity, parenchymal structure, free fluid in the abdominal cavity and focal lesions. Elastography (FibroScan) adds assessment of fibrosis degree. With abnormal blood and imaging results, hepatological consultation is indicated.

When is liver biopsy needed in alcoholic liver disease?

Liver biopsy in alcoholic liver disease is indicated when non-invasive methods (elastography, laboratory indices) give equivocal results regarding fibrosis degree, when the clinical picture suggests more severe hepatitis than non-invasive tests indicate, when co-existing liver disease of another aetiology is suspected, or when results will influence critical clinical decisions such as transplant qualification.

Liver tests with alcohol misuse – which to order and when

Assessing liver status in a person who drinks alcohol or is dependent on it is not a simple task of ordering a few standard tests. It is a multi-layered diagnostic process in which individual investigations complement each other and together create the clinical picture on which safe treatment can be planned. Knowing what to test, in what sequence and how to interpret results – both normal and abnormal – is important for patients, their families and physicians referring to addiction treatment.

Layer one: basic blood tests

Every liver assessment in a person who drinks alcohol starts with laboratory tests. The standard panel when alcoholic liver damage is suspected includes markers of cellular damage, indices of synthetic function and general parameters that may indicate liver disease complications.

Markers of hepatocyte damage

GGT (gamma-glutamyltransferase) – the most sensitive and earliest-responding marker of alcohol misuse. Rises in 70-80% of heavy drinkers, often as the only abnormality in early damage. Normalises after 4-8 weeks of abstinence. Limitation: non-specific – also rises with medications, thyroid disease and obesity.

AST and ALT (aminotransferases) – reflect necrosis or damage to hepatocytes. AST/ALT ratio above 2 is characteristic of alcoholic liver disease. In ALD they rarely exceed 300-400 IU/l – higher values suggest a co-existing cause.

ALP (alkaline phosphatase) – marker of cholestasis and biliary tract damage. Isolated elevated ALP with normal AST/ALT and GGT should prompt consideration of bone disease or primary biliary disease (PBC, PSC).

Markers of synthetic function

Albumin – protein synthesised exclusively by hepatocytes, with a half-life of 20 days. Hypoalbuminaemia (below 3.5 g/dl) indicates chronic impairment of synthesis. A component of the Child-Pugh score.

INR – reflects the liver’s ability to synthesise clotting factors II, VII, IX and X. INR above 1.5 indicates significant impairment. A component of the Maddrey discriminant function and MELD score.

Bilirubin (total and direct) – bilirubin above 3 mg/dl is clinically visible as jaundice. High bilirubin with normal or moderately elevated aminotransferases may indicate cholestasis. Rise in direct bilirubin indicates biliary excretion disturbance.

General and haematological parameters

Full blood count with differential – macrocytosis (MCV above 100 fl) is a common finding in alcoholism resulting from direct toxic effects on erythropoiesis and folate deficiency. Thrombocytopaenia (PLT below 150,000/ul) may indicate hypersplenism or direct marrow toxicity from alcohol.

Creatinine and electrolytes – rising creatinine in cirrhosis may indicate hepatorenal syndrome. Metabolic alkalosis with hypokalaemia is common in alcoholism.

Layer two: specific markers of alcohol misuse

CDT (Carbohydrate-Deficient Transferrin) – high specificity (90-97%) for alcohol misuse. Rises after consuming above 50-80 g ethanol daily for at least 2 weeks; normalises after 2-4 weeks of abstinence. Used in transplant programme abstinence monitoring and differential diagnosis of elevated GGT.

PEth (phosphatidylethanol) – a direct biomarker of ethanol action in erythrocytes, with very high specificity (above 99%) and sensitivity with intensive drinking. Remains detectable for 3-4 weeks after consumption. Increasingly used in transplant programmes as a more sensitive and specific marker than CDT.

EtG/EtS in urine – ethanol metabolites detectable in urine for 24-80 hours after consumption. Very sensitive – may be positive even with trace amounts from hygiene products. Used as short-term abstinence markers.

Layer three: imaging

Abdominal ultrasound – first-line investigation. Assesses liver size (normal: up to 15 cm at mid-clavicular line), parenchymal echogenicity (hyperechoic “bright liver” with steatosis), free fluid (ascites), splenomegaly (portal hypertension) and focal lesions suggesting hepatocellular carcinoma. Limitation: operator-dependent and poorly differentiates fibrosis degrees.

Liver elastography (FibroScan, ARFI) – non-invasive assessment of liver stiffness as an indirect fibrosis marker. FibroScan result in kPa correlates with fibrosis stage (F0-F4 on the Metavir scale). Method of choice for non-invasive fibrosis assessment, replacing biopsy in many cases. Results may be overestimated with active inflammation, within 2 hours of alcohol consumption or with BMI above 30.

CT or MRI of the abdomen – indicated with equivocal ultrasound results, suspected focal lesions or need for precise vascular assessment. Standard for hepatocellular carcinoma diagnosis.

Viral markers – a mandatory component

Every person with alcoholic liver disease should be tested for viral hepatitis. HCV and HBV are significantly more common in the alcohol-dependent population and act synergistically with alcohol to accelerate progression to cirrhosis.

Minimum viral panel: anti-HCV, HBsAg, anti-HBs, anti-HBc. With positive anti-HCV: HCV RNA testing to confirm active infection. With HBsAg-positive: HBeAg, anti-HBe and HBV DNA.

Non-invasive fibrosis indices calculated from routine tests

FIB-4 = age (years) × AST (IU/l) / PLT (10⁹/l) × √ALT (IU/l). Below 1.30: high negative predictive value for advanced fibrosis. Above 2.67: high specificity for advanced fibrosis. Grey zone 1.30-2.67: further elastography workup needed.

APRI (AST to Platelet Ratio Index) = AST / upper limit of normal AST × 100 / PLT (10⁹/l). Above 1.0 suggests significant fibrosis; above 2.0 suggests cirrhosis – with moderate sensitivity and specificity.

How test results influence the treatment plan

Normal tests with no clinical features of liver disease – detox location, medication choice and monitoring intensity require no modification. Abnormal liver tests, particularly with impaired synthetic function, modify all of these decisions. Advanced fibrosis or cirrhosis on elastography indicates the need for regular hepatological follow-up in parallel with alcohol treatment.

Pharmacotherapy for addiction – naltrexone, acamprosate, disulfiram – must take liver test results into account. Alcohol therapy is possible at every stage of liver disease – provided the treatment plan is based on a current hepatological assessment.

Frequently asked questions

Which blood tests should be ordered when alcoholic liver damage is suspected?

Full blood count, AST, ALT, GGT, bilirubin, albumin, INR, creatinine and electrolytes. This panel assesses both cellular damage and synthetic function. With abnormal results: extend to viral markers and imaging.

Is blood testing alone sufficient to assess liver status?

No – blood tests and ultrasound complement each other. Ultrasound assesses size, echogenicity and structure. Elastography adds fibrosis assessment. Together they give a fuller picture than either alone.

What is CDT and when is it used?

Carbohydrate-deficient transferrin – a high-specificity alcohol misuse marker (90-97%). Rises after over 50-80 g ethanol daily for 2 weeks; normalises after 2-4 weeks of abstinence. Used in transplant programme abstinence monitoring.

When is liver biopsy needed?

When non-invasive methods give equivocal fibrosis results, when co-existing disease of another aetiology is suspected, or when results will influence critical clinical decisions such as transplant qualification.

References

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.
Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance. Hepatology. 2020;71(1):306-333.
Vallet-Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis. Hepatology. 2007;46(1):32-36.
Sterling RK, et al. Development of a simple noninvasive index to predict significant fibrosis. Hepatology. 2006;43(6):1317-1325.
Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings. Alcohol Clin Exp Res. 2010;34(6):955-967.
Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide. Addiction. 2003;98(Suppl 2):51-61.
Nyblom H, et al. High AST/ALT ratio may indicate advanced alcoholic liver disease. Alcohol Alcohol. 2004;39(4):336-339.

Confidential Clinical Contact

CLINICAL INQUIRY

The form is intended for submitting a clinical inquiry. Messages are delivered directly to the team responsible for treatment coordination.

Related Treatment Areas

Alcohol Addiction Treatment

Alcohol Detox

Alcohol Therapy

Clinical Contact

Q: Which blood tests should be ordered when alcoholic liver damage is suspected?

The basic panel includes: full blood count with differential, AST, ALT, GGT, total and direct bilirubin, albumin, INR, creatinine and electrolytes. Additionally alkaline phosphatase (ALP) and LDH. This panel assesses both the degree of hepatocyte damage and hepatic synthetic function. With abnormal results, extending the workup to include viral markers and imaging is indicated.

Q: What is CDT and when is it used?

CDT (Carbohydrate-Deficient Transferrin) is a marker of alcohol misuse with higher specificity than GGT (90-97%). It rises after consuming more than 50-80 g of ethanol daily for at least 2 weeks and normalises after 2-4 weeks of abstinence. Used as an objective abstinence monitoring marker in transplant programmes and in differential diagnosis of elevated GGT of unclear aetiology.

Contact with the center is intended for providing information regarding inpatient treatment and coordinating next steps in a confidential and non-binding manner.

Scope of Treatment and Informational Nature of Content

Inpatient treatment provided at Zeus Detox & Rehab is clinical in nature and focuses on medical stabilization, psychiatric assessment, and therapeutic intervention appropriate to the diagnosed condition and stage of the disorder. The scope and structure of treatment are determined individually by the clinical team based on the patient’s current health status and applicable medical standards.

The information presented on this website is for educational and informational purposes only. It does not constitute medical advice and should not be used as a basis for self-directed treatment decisions. Addiction and mental health treatment require individual medical qualification and clinical assessment.

Content Author

Content published on this website is prepared by the interdisciplinary clinical team of Zeus Detox & Rehab in collaboration with physicians, psychiatrists, psychotherapists, clinical psychologists, and medical staff. Materials are developed on the basis of current medical knowledge and clinical experience in inpatient addiction treatment.

Clinical Team Zeus Detox & Rehab

000000258902 - Our Masovian Voivodeship registration number

Clinical contact
Confidential consultation • 24/7

+48 537 677 773

Liver tests with alcohol misuse – which to order and when

Liver tests with alcohol misuse – which to order and when